Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
about
Risk impact of edoxaban in the management of stroke and venous thromboembolismComparative risk impact of edoxaban in the management of stroke and venous thromboembolismDirect-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine PhysiciansEdoxaban in venous thromboembolism and stroke prevention: an appraisalManagement of Venous Thromboembolism: Recent Advances in Oral Anticoagulation TherapyProfiles of direct oral anticoagulants and clinical usage-dosage and dose regimen differencesNovel oral anticoagulants and the 73rd anniversary of historical warfarinStroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulantsUpdate on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current EvidenceNew oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectivenessSafety of new oral anticoagulant drugs: a perspectiveAn evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillationSpecial considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillationDirect oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced ageDrug-induced liver injury: Towards early prediction and risk stratificationTwice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteriaNew and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome.New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplastyEdoxaban: an update on the new oral direct factor Xa inhibitor.A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation--full speed ahead or proceed with caution?Edoxaban: an investigational factor xa inhibitor.Reversal of novel oral anticoagulants in patients with major bleeding.Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers.A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty.Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.Treatment options for venous thromboembolism: lessons learnt from clinical trials.A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery.Are the novel anticoagulants better than warfarin for patients with atrial fibrillation?Bleeding risk and mortality of edoxaban: a pooled meta-analysis of randomized controlled trials.Laboratory measurement of the anticoagulant activity of edoxaban: a systematic reviewDirect oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation.New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesThe effect of rifampin on the pharmacokinetics of edoxaban in healthy adults.A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits.Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation.Edoxaban.Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism--the Hokusai-VTE phase 3 studyNovel anticoagulants in atrial fibrillation stroke prevention
P2860
Q26738846-3791D362-9DF4-4F9C-9D22-671EE65D015EQ26746233-1C6157A6-E7EA-497F-BD84-7D4B5C9B80D1Q26746917-8775622E-E651-44B3-8091-5D17498B15DBQ26751263-AB6E9AFD-7DE8-4355-9474-5AB9696F5BBEQ26766303-49CD3CFC-2164-4DB0-887C-E42E273666EFQ26766354-16EE3728-B9B3-4858-BB46-4BA58AC857CAQ26771544-EEAA19F8-541C-4979-A288-F5C0621396CEQ26781181-97A9D345-C7D7-43C5-A7A6-006AF3B12B8DQ26782483-15880D41-B541-41B5-9653-0BB525EEAF1EQ26863548-D3391A67-D3B2-4A14-9025-0DA854454965Q27016072-C0CB2751-90E2-493B-ADF8-6BE1274EF877Q27027953-07D35050-CBB1-429E-A0F2-64B93B940A10Q28072542-E55FF7D8-C08C-4324-BF5A-8D0C4BDF5A5CQ28079930-7C841E6E-6791-4839-AD00-12A6EC1160E6Q28468389-DB3C7761-5E54-4044-B9BA-B69836D2F0FEQ28539517-44134958-E784-48EB-B1C1-1460C0F85DC9Q33397359-5B3911C4-6F8D-4146-9747-8667A4971156Q33891915-9725BC02-DCC7-446C-82C4-27A7B0BFE941Q33935409-3BCFA7C5-A742-4C27-9211-B3BE246D2C28Q34109813-D7516F79-93F0-4D12-AB80-B6B9E058DA72Q34306430-257198F3-537C-487F-A140-170CF4EA3BCFQ34326655-5D344DDF-6837-451F-97E6-C5D648E011F1Q34620374-893EDDAA-4F5B-4209-BD20-E3993AA50B23Q34622654-2165E559-0B76-4520-9DB4-A12055FEC54CQ34627780-0C028B30-1E77-4C21-8FE4-8DF9CA053389Q34651051-1720097D-C808-4EF8-9F5A-D4CEE78CCF9EQ34653407-3A0633E5-5E20-45E2-A680-3750020CD69FQ34694544-5B022232-37AE-4663-902F-B7ED7D90A224Q35047476-AAC95A0B-0AD3-4898-B692-DA4FE749E5DFQ35062047-F1F0B1F0-D4C2-4E6C-A23E-096DA2DB2610Q35149499-E0805AB9-6C3F-46F3-AAD0-B0DCBAE05162Q35559027-5FE1871C-4979-4FFD-9A48-1D4E2757158BQ35746798-1C617A79-6E0A-4943-BE75-19DAA3CD1B48Q35752611-B0F9A5D5-2693-47D5-AD9F-4EABF1D08C60Q35807991-F9CDF0EC-C68D-433C-80AA-9FD597057477Q35986742-8185FCBB-CAFC-4128-99B7-88D39B83826DQ36100271-B5668990-33D8-4534-953C-9DE5F1915192Q36109959-094B2088-719A-421C-9BD3-9301770179DEQ36410089-5BF62496-DD32-4B99-B166-989F0E4582D5Q36443814-E0B36266-4B64-49E4-BB45-DDC08323EC1E
P2860
Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Clinical safety, tolerability, ...... doxaban in healthy volunteers.
@ast
Clinical safety, tolerability, ...... doxaban in healthy volunteers.
@en
Clinical safety, tolerability, ...... doxaban in healthy volunteers.
@nl
type
label
Clinical safety, tolerability, ...... doxaban in healthy volunteers.
@ast
Clinical safety, tolerability, ...... doxaban in healthy volunteers.
@en
Clinical safety, tolerability, ...... doxaban in healthy volunteers.
@nl
prefLabel
Clinical safety, tolerability, ...... doxaban in healthy volunteers.
@ast
Clinical safety, tolerability, ...... doxaban in healthy volunteers.
@en
Clinical safety, tolerability, ...... doxaban in healthy volunteers.
@nl
P2093
P2860
P356
P1476
Clinical safety, tolerability, ...... doxaban in healthy volunteers.
@en
P2093
Hiroshi Masumoto
Jeanne Mendell-Harary
Koichiro Ogata
Masaya Tachibana
Masazumi Kojima
Satoshi Kunitada
Toshihiro Oguma
P2860
P304
P356
10.1177/0091270009351883
P577
2010-01-15T00:00:00Z